Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the appointment of Chief Business Officer Carl Foster. Based in our U.S. office, Foster will be responsible for expanding strategic partnerships for novel drug target discoveries and first-in-class lead candidate identifications.
Standigm was named the winner of a Gold Stevie® Award in the Pharmaceutical category and a Bronze Stevie® Award in the Computer Software category in The 19th Annual International Business Awards® today.
Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing of a Memorandum of Understanding (MOU) with Merck Korea, for AI-based drug discovery research. The MOU signing took place on May 30 at the headquarters of Standigm, attended by Sojeong Yun, CEO of Standigm, and Stephen Namkoo Lee, the Head of Science and Lab Solutions, Life Science business sector of Merck Korea.